Trial Profile

Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temozolomide (Primary)
Indications Glioma
Focus Therapeutic Use
Acronyms TCLGG

Most Recent Events

22 Sep 2016 Primary endpoint (Progression free survival at 12 and 24 months) has not been met,according to the results published in the Tumori.
22 Sep 2016 Results published in the Tumori
07 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com